

論文等 (2022 年 1 月-2022 年 12 月)

著書

- **輸血. イヤーノート 2022, G11-G18**
緒方正男:
- **造血幹細胞移植後のウイルス感染症と対策**
緒方正男 血液疾患最新の治療 2023-2025, 松村到、張替秀郎、神田善伸 (編集), 南江堂. 2022: 267-270

総説

- **造血幹細胞移植後 HHV-6B 脳炎の病態と治療**
緒方正男、血液内科 2022, 85: 335-341
- **造血幹細胞移植と HHV-6B**
緒方正男、臨床とウイルス (Clinical Virology) 2022.10 50(4), 197-202
- **同種造血幹細胞移植後の脳・神経合併症 -ウイルス性脳炎と白質脳症を中心として-**
緒方正男、日本造血・免疫細胞療法学会雑誌 in press
- **十二指腸濾胞性リンパ腫の特徴と治療**
佐分利益穂、血液内科 2022, 84: 326-332

原著

- **Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group**
Fuji S, Hirakawa T, Takano K, Doki N, Sawa M, Kanda Y, Uchida N, Ara T, Miyamoto T, Eto T, Matsuoka KI, Kawakita T, Ozawa Y, Katayama Y, Onizuka M, Fukuda T, Atsuta Y, Nakasone H
Bone Marrow Transplant. 2022 Mar;57(3):479-486. doi: 10.1038/s41409-022-01569-x. Epub 2022 Jan 17. PMID: 35039621.
- **Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation**
Onizuka M, Fujii N, Nakasone H, Ogata M, Atsuta Y, Suzuki R, Uchida N, Ohashi K, Ozawa Y, Eto T, Ikegame K, Nakamae H, Inoue M, Fukuda T; Transplant Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Int J Hematol. 2022 Apr;115(4):534-544. doi: 10.1007/s12185-021-03282-9. Epub 2022 Jan 28. PMID: 35088350.
- **Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group.**
Kimura SI, Kameda K, Harada K, Saburi M, Okinaka K, Shinohara A, Uchida N, Nishijima A, Ozawa Y, Tanaka M, Kuriyama T, Katayama Y, Sawa M, Ikegame K, Kawakita T, Kanda Y, Nakamae H, Ara T, Kimura T, Sato A, Fukuda T, Atsuta Y, Nakasone

H.

Transplant Cell Ther. 2022 Apr;28(4):209.e1-209.e9. doi: 10.1016/j.jtct.2021.12.020. Epub 2022 Jan 5. PMID: 34995815.

- **RAISING is a high-performance method for identifying random transgene integration sites**

Wada Y, Sato T, Hasegawa H, Matsudaira T, Nao N, Coler-Reilly ALG, Tasaka T, Yamauchi S, Okagawa T, Momose H, Tanio M, Kuramitsu M, Sasaki D, Matsumoto N, Yagishita N, Yamauchi J, Araya N, Tanabe K, Yamagishi M, Nakashima M, Nakahata S, Iha H, Ogata M, Muramatsu M, Imaizumi Y, Uchimar K, Miyazaki Y, Konnai S, Yanagihara K, Morishita K, Watanabe T, Yamano Y, Saito M

Commun Biol. 2022 Jun 2;5(1):535. doi: 10.1038/s42003-022-03467-w. PMID: 35654946.

- **Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.**

Sumimoto T, Nakahara R, Suzuki Y, Tanaka R, Yoshida N, Ogata M, Itoh H.

Ther Drug Monit. 2022 Jun 1;44(3):419-429. doi: 10.1097/FTD.0000000000000922. PMID: 34469417.

- **Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience**

Saburi M, Sakata M, Takata H, Miyazaki Y, Kawano K, Sasaki H, Abe M, Kohno K, Soga Y, Nagamatsu K, Ono K, Nakayama T, Ohtsuka E.

Leuk Lymphoma. 2022 Jun 10:1-5. doi: 10.1080/10428194.2022.2086250. Epub ahead of print. PMID: 35687847.

- **NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia**

Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H.

Int J Hematol. 2022 Aug;116(2):199-214. doi: 10.1007/s12185-022-03328-6. Epub 2022 Apr 4. PMID: 35377134.

- **Oral HDAC Inhibitor Tucidinostat (HBI-8000) in Patients with Relapsed or Refractory Adult T-cell Leukemia/Lymphoma: Phase IIb Results.**

Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, Choi I, Imaizumi Y, Kato K, Kurosawa M, Kusumoto S, Miyagi T, Ohtsuka E, Sasaki O, Shibayama H, Shimoda K, Takamatsu Y, Takano K, Yonekura K, Makita S, Taguchi J, Gillings M, Onogi H, Tobinai K.

Cancer Sci. 2022 Aug;113(8):2778-2787. doi: 10.1111/cas.15431. Epub 2022 Jun 7. PMID: 35579212; PMCID: PMC9357668.

- **Impact of inflammation on intra-individual variation in trough voriconazole concentration in patients with hematological malignancies**

Maeda Y, Tanaka R, Tatsuta R, Takano K, Hashimoto T, Ogata M, Hiramatsu K, Itoh H.

Biol Pharm Bull. 2022;45(8):1084-1090. doi: 10.1248/bpb.b22-00097. PMID: 35908890.

- **CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab**

treatment

Sakamoto Y, Ishida T, Masaki A, Murase T, Ohtsuka E, Takeshita M, Muto R, Iwasaki H, Ito A, Kusumoto S, Nakano N, Tokunaga M, Yonekura K, Tashiro Y, Iida S, Utsunomiya A, Ueda R, Inagaki H.

Hematol Oncol. 2022 Aug 31. doi: 10.1002/hon.3072. Epub ahead of print. PMID: 36043457.

- **Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).**

Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Ohtsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H.

Cancer Sci. 2022 Sep;113(9):3267-3270. doi: 10.1111/cas.15484. Epub 2022 Jul 31. PMID: 35909244; PMCID: PMC9459263.

- **Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.**

Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, Ishida T.

Haematologica. 2022 Oct 1;107(10):2418-2431. doi: 10.3324/haematol.2021.280352. PMID: 35417939; PMCID: PMC9521232.

- **Discordance in the morphologic diagnosis of lymphocytes in HTLV-1-infected individuals.**

Fuji S, Muta M, Ikeda E, Sakai R, Hagiwara Y, Zaizen K, Makiyama J, Choi I, Takano K, Koh KR, Ishikawa J.

Int J Lab Hematol. 2022 Oct;44(5):e250-e252. doi: 10.1111/ijlh.13915. Epub 2022 Jun 14. PMID: 35702819.

- **Landscape of immunoglobulin heavy chain gamma gene class switch recombination in patients with adult T-cell leukemia-lymphoma.**

Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, Ishida T.

Haematologica. 2022 Nov 24. doi: 10.3324/haematol.2022.281435. Epub ahead of print. PMID: 36420800.

- **Clinicopathological findings, prognosis, and Epstein-Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders.**

Kimura S, Oshiro Y, Iwasaki H, Kadowaki M, Ogata M, Daa T, Sakata T, Kawauchi S, Wang Z, Takamatsu Y, Takeshita M.

BMC Cancer. 2022 Dec 22;22(1):1342. doi: 10.1186/s12885-022-10358-0. PMID: 36544095.

- **Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial.**

Okinaka K, Akeda Y, Inamoto Y, Fuji S, Ito A, Tanaka T, Kurosawa S, Kim SW, Tanosaki R, Yamashita T, Ohwada C, Kurata K, Mori T, Onozawa M, Takano K, Yokoyama H, Koh K, Nagafuji K, Nakayama K, Sakura T, Takahashi T, Oishi K, Fukuda T.

Clin Microbiol Infect. 2022 Dec 8:S1198-743X(22)00611-5. doi: 10.1016/j.cmi.2022.12.007.

- **Successful treatment with tirabrutinib for relapsed Bing-Neel syndrome following high-dose methotrexate and craniospinal irradiation.**
Saburi M, Sakata M, Okuhiro K, Kawano K, Uesugi S, Wada J, Urabe S, Saburi Y, Ohtsuka E
J Clin Exp Hematop. 2022;62(3):181-186. doi: 10.3960/jslrt.22018. PMID: 36171098.
- **Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing-Neel syndrome.**
Saburi M, Saburi Y, Kawano K, Sato R, Urabe S, Ohtsuka E
Int J Hematol. 2022 Apr;115(4):585-589. doi: 10.1007/s12185-021-03246-z. Epub 2021 Oct 26. PMID: 34699012.
- **A case of orofacial swelling accompanied by sarcoid-like reaction due to chronic active Epstein-Barr virus infection.**
Nishiyori R, Saito K, Ishibashi M, Matsubara E, Okuhiro K, Takano K, Imadome KI, Takaji R, Nishino I, Nishida H, Daa T, Oki R, Shimizu F, Goto-Umeki M, Goto M, Hatano Y.
Eur J Dermatol. 2022 Apr 1;32(2):277-278. English. doi: 10.1684/ejd.2022.4248. PMID: 35866916.
- **Incidentally detected extramedullary plasmacytoma of the gallbladder: a case report and literature review.**
Ono H, Iwatsu S, Otsuka E, Kato Y.
Intern Med. 2022 Sep 13. doi: 10.2169/internalmedicine.0035-22. Online ahead of print. PMID: 36104190
- **ALK 陽性未分化大細胞リンパ腫に対する brentuximab vedotin 併用 CHP 療法後の残存病変に奏効した alectinib 単剤療法**
坂田 真規, 佐分利 益穂, 河野 克也, 高田 寛之, 宮崎 泰彦, 長松 顕太郎, 蒲地 綾子, 大塚 英一
臨床血液, 2022, 63(8): 855-859
- **前房蓄膿を伴った難治性びまん性大細胞型B細胞リンパ腫に対する自家末梢血幹細胞移植併用busulfan/thiotepa療法**
児玉洋資, 佐分利益穂, 丸山莉果, 坂田真規, 高田寛之, 宮崎泰彦, 河野克也, 和田純平, 卜部省悟, 波津久智伸, 大塚英一
臨床血液 2022, 63 (10): 1409-1414,
- **環状鉄芽球増加と異形成の乏しい骨髓像が診断契機となった飲酒に伴うビタミン B6 欠乏性鉄芽球性貧血**
児玉 佳愛, 佐分利 益穂, 山下佐知子, 姫野君枝, 河野 克也, 大塚 英一
日本検査血液学会雑誌, 2022, 23(1): 67-72
- **本態性血小板血症とびまん性大細胞型 B 細胞リンパ腫を合併した 3 例**
佐分利 能生, 大塚 英一, 宮崎 泰彦, 河野 克也, 卜部 省悟, 熊野 弘毅
大分県立病院医学雑誌, 2022, 49: 34-39
- **初回治療後早期かつ自家末梢血幹細胞移植後早期に再発した難治性濾胞性リンパ腫に対する lenalidomide, rituximab(R2)療法が奏効した一例**
坂田 真規, 佐分利 益穂, 和田 純平, 河野 克也, 奥廣和樹, 高田寛之, 宮崎 泰彦, 卜部 省悟, 大塚 英一
大分県立病院医学雑誌, 2022, 49: 40-45
- **3か所の神経支配領域に発症した多発性帯状疱疹の 1 例**
岡本修, 柳井優花, 長松顕太郎, 小野敬司, 工藤洋一, 蒲地綾子, 小松栄二, 橋本祐之
臨床皮膚科 2022, 76 (8) : 643-649.
- **全身状態不全患者に生じた単純ヘルペス性毛包炎の 1 例**

岡本修、柳井優花、長松頭太郎、小野敬司、蒲池綾子、橋本祐之
皮膚科の臨床 2022, 64 (6) : 1001-1004.

- **口腔内と消化管の多発潰瘍で発症したFLP1L1::PDGFR陽性慢性好酸球性白血病**

長松頭太郎、柳井優花、蒲池綾子、小野敬司

臨床血液 2022, 63 (11) :1503-1507.

Correspondence

- **Long-term follow-up of patients with ATL after autologous stem cell transplantation**

Utsunomiya A, Tokunaga M, Nakano N, Fujiwara H, Miyamoto T, Ogata M, Miyazaki Y, Ishitsuka K, Sakaida E, Taji H, Wakayama T, Ichinohe T, Fukuda T, Atsuta Y, Kato K, Yoshimitsu M

Bone Marrow Transplant. 2022 Jan 23. doi: 10.1038/s41409-021-01412-9. Epub ahead of print. PMID: 35066568.

- **Thrombophlebitis Migrans As the Prodrome of Adult T-Cell Leukemia-Lymphoma.**

Matsuda-Hirose H, Nashimoto Y, Tanabe A, Ogata M, Iwao M, Mizukami K, Nishida H, Hatano Y.

Ann Dermatol. 2022 Aug;34(4):312-314. doi: 10.5021/ad.20.184. PMID: 35948337.

(参考) 昨年の業績集に Online ahead of print で記載し、その後、巻・号が追加された論文、および記載もれの業績

- **Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.**

Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara H, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsunashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H.

Blood adv. 2022 Jan 11;6(1):238-247. doi: 10.1182/bloodadvances.2021004292. PMID: 34448807; PMCID: PMC8753195.

- **Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab**

Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Utsunomiya A, Ueda R, Ishida T.

Brit J Haematol. 2022 Feb;196(3):629-638. doi: 10.1111/bjh.17895. Epub 2021 Oct 10. PMID: 34632569.

- **High-throughput simultaneous quantification of five azole anti-fungal agents and one active metabolite in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry.**

Tanaka R, Shiraiwa K, Takano K, Ogata M, Honda S, Yoshida N, Okuhiro K, Yoshida M, Narahara K, Kai M, Tatsuta R, Itoh H.

Clin Biochem 2022 Jan;99:87-96. doi: 10.1016/j.clinbiochem.2021.10.010. Epub 2021 Oct 27. PMID: 34715112.

- **Fungal biomarker monitoring and CT scans for early detection of invasive fungal disease in neutropenic hematological patients.**

Kimura SI, Kanda Y, Oyake T, Yamaguchi H, Fujiwara SI, Okamoto A, Fujita H, Saburi Y, Tamura K

J Infect. 2022 Jan;84(1):80-86. doi: 10.1016/j.jinf.2021.10.018. Epub 2021 Oct 25. PMID: 34710391.